• Something wrong with this record ?

Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study

AS. Pires-Luis, P. Martinek, R. Alaghehbandan, K. Trpkov, EM. Comperat, DM. Perez Montiel, S. Bulimbasic, J. Lobo, R. Henrique, T. Vanecek, K. Pivovarcikova, K. Michalova, T. Pitra, M. Hora, A. Marques, JM. Lopes, J. Rogala, J. Mareckova, M....

. 2020 ; 27 (5) : 303-310. [pub] -

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc21012169

The diagnosis of primary adenocarcinoma of the urinary bladder may be challenging in routine practice. These tumors may morphologically and immunohistochemically overlap with urachal adenocarcinoma and colorectal adenocarcinoma. Further, their genetic background is poorly understood. We systematically searched the PubMed database for results of complex genetic evaluation of primary bladder adenocarcinoma subtypes. Subsequently, we designed our own series of bladder lesions. We evaluated 36 cases: 16 primary enteric-type adenocarcinomas, 7 urachal enteric adenocarcinomas, 3 primary mucinous/colloid adenocarcinomas, and 10 intestinal-type metaplasia/villous adenoma. Detailed clinical data were collected, and all cases were examined using targeted next-generation sequencing. On the basis of the literature, the first mutated gene in these tumors was reported to be KRAS in 11.3% of cases, followed by TERT promoter mutations in 28.5%. In addition to KRAS and TERT, other genes were also found to be frequently mutated in primary bladder adenocarcinoma, including TP53, PIK3CA, CTNNB1, APC, FBXW7, IDH2, and RB1. In our series, the most frequent gene mutations in primary enteric-type adenocarcinomas were as follows: TP53 (56%); BRCA2, KMT2B (both 33%); NOTCH2, KDR, ARID1B, POLE, PTEN, KRAS (all 28%); in urachal enteric adenocarcinoma they were as follows: TP53 (86%); PTEN, NOTCH (both 43%); in primary mucinous/colloid adenocarcinomas they were as follows: KRAS, GRIN2A, AURKB (all 67%); and, in intestinal-type metaplasia/villous adenoma, they were as follows: APC, PRKDC (both 60%); ROS1, ATM, KMT2D (all 50%). No specific mutational pattern was identified using cluster analysis for any of the groups. Herein, we describe the pathologic features and immunohistochemical staining patterns traditionally used in the differential diagnoses of glandular lesions of the bladder in routine surgical pathology. We outline the mutational landscape of these lesions as an aggregate of published data with additional data from our cohort. Although diagnostically not discriminatory, we document that the most common genetic alterations shared between these glandular neoplasms include TP53, APC (in the Wnt pathway), and KRAS (in the MAPK pathway) mutations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012169
003      
CZ-PrNML
005      
20210507101537.0
007      
ta
008      
210420s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/PAP.0000000000000268 $2 doi
035    __
$a (PubMed)32520749
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pires-Luis, Ana S $u Department of Pathology, Centro Hospitalar de Vila Nova de Gaia-Espinho, Vila Nova de Gaia $u Cancer Biology and Epigenetics Group (CBEG), IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC) $u Departments of Microscopy
245    10
$a Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study / $c AS. Pires-Luis, P. Martinek, R. Alaghehbandan, K. Trpkov, EM. Comperat, DM. Perez Montiel, S. Bulimbasic, J. Lobo, R. Henrique, T. Vanecek, K. Pivovarcikova, K. Michalova, T. Pitra, M. Hora, A. Marques, JM. Lopes, J. Rogala, J. Mareckova, M. Michal, O. Hes
520    9_
$a The diagnosis of primary adenocarcinoma of the urinary bladder may be challenging in routine practice. These tumors may morphologically and immunohistochemically overlap with urachal adenocarcinoma and colorectal adenocarcinoma. Further, their genetic background is poorly understood. We systematically searched the PubMed database for results of complex genetic evaluation of primary bladder adenocarcinoma subtypes. Subsequently, we designed our own series of bladder lesions. We evaluated 36 cases: 16 primary enteric-type adenocarcinomas, 7 urachal enteric adenocarcinomas, 3 primary mucinous/colloid adenocarcinomas, and 10 intestinal-type metaplasia/villous adenoma. Detailed clinical data were collected, and all cases were examined using targeted next-generation sequencing. On the basis of the literature, the first mutated gene in these tumors was reported to be KRAS in 11.3% of cases, followed by TERT promoter mutations in 28.5%. In addition to KRAS and TERT, other genes were also found to be frequently mutated in primary bladder adenocarcinoma, including TP53, PIK3CA, CTNNB1, APC, FBXW7, IDH2, and RB1. In our series, the most frequent gene mutations in primary enteric-type adenocarcinomas were as follows: TP53 (56%); BRCA2, KMT2B (both 33%); NOTCH2, KDR, ARID1B, POLE, PTEN, KRAS (all 28%); in urachal enteric adenocarcinoma they were as follows: TP53 (86%); PTEN, NOTCH (both 43%); in primary mucinous/colloid adenocarcinomas they were as follows: KRAS, GRIN2A, AURKB (all 67%); and, in intestinal-type metaplasia/villous adenoma, they were as follows: APC, PRKDC (both 60%); ROS1, ATM, KMT2D (all 50%). No specific mutational pattern was identified using cluster analysis for any of the groups. Herein, we describe the pathologic features and immunohistochemical staining patterns traditionally used in the differential diagnoses of glandular lesions of the bladder in routine surgical pathology. We outline the mutational landscape of these lesions as an aggregate of published data with additional data from our cohort. Although diagnostically not discriminatory, we document that the most common genetic alterations shared between these glandular neoplasms include TP53, APC (in the Wnt pathway), and KRAS (in the MAPK pathway) mutations.
650    _2
$a adenokarcinom $x genetika $x patologie $7 D000230
650    _2
$a mucinózní adenokarcinom $x genetika $x patologie $7 D002288
650    _2
$a adenom $x genetika $x patologie $7 D000236
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a střevní nádory $x genetika $x patologie $7 D007414
650    _2
$a metaplazie $x genetika $x metabolismus $7 D008679
650    _2
$a nádory močového měchýře $x genetika $x patologie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Martinek, Petr $u Departments of Pathology
700    1_
$a Alaghehbandan, Reza $u Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC
700    1_
$a Trpkov, Kiril $u Department of Pathology, University of Calgary and Calgary Laboratory Services, Calgary, AB, Canada
700    1_
$a Comperat, Eva M $u Department of Pathology, Sorbonne Université, Service d'Anatomie et Cytologie Pathologiques, Hôpital Tenon, Paris, France
700    1_
$a Perez Montiel, Delia M $u Department of Pathology, Institute Nacional de Cancerologia, INCAN, Mexico City, Mexico
700    1_
$a Bulimbasic, Stela $u Department of Pathology, School of Medicine, Zagreb, Croatia
700    1_
$a Lobo, João $u Cancer Biology and Epigenetics Group (CBEG), IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC) $u Department of Pathology, Portuguese Oncology Institute of Porto (IPOP) $u Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP)
700    1_
$a Henrique, Rui $u Cancer Biology and Epigenetics Group (CBEG), IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC) $u Department of Pathology, Portuguese Oncology Institute of Porto (IPOP) $u Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS-UP)
700    1_
$a Vanecek, Tomas $u Departments of Pathology
700    1_
$a Pivovarcikova, Kristyna $u Departments of Pathology
700    1_
$a Michalova, Kvetoslava $u Departments of Pathology
700    1_
$a Pitra, Tomas $u Urology, Charles University in Prague, Faculty of Medicine in Plzeň, Plzeň, Czech Republic
700    1_
$a Hora, Milan $u Urology, Charles University in Prague, Faculty of Medicine in Plzeň, Plzeň, Czech Republic
700    1_
$a Marques, Ana $u Faculty of Medicine, University of Porto $u Department of Pathology, Centro Hospitalar e Universitário de São João, Porto, Portugal
700    1_
$a Lopes, Jose M $u Faculty of Medicine, University of Porto $u Department of Pathology, Centro Hospitalar e Universitário de São João, Porto, Portugal
700    1_
$a Rogala, Joanna $u Departments of Pathology
700    1_
$a Mareckova, Jana $u Departments of Pathology
700    1_
$a Michal, Michal $u Departments of Pathology
700    1_
$a Hes, Ondrej $u Departments of Pathology
773    0_
$w MED00000158 $t Advances in anatomic pathology $x 1533-4031 $g Roč. 27, č. 5 (2020), s. 303-310
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32520749 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101537 $b ABA008
999    __
$a ok $b bmc $g 1650527 $s 1132548
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 27 $c 5 $d 303-310 $e - $i 1533-4031 $m Advances in anatomic pathology $n Adv Anat Pathol $x MED00000158
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options